Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares ...

Dr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss ...

As a pro athlete, Caitlin Clark has access to some of the most innovative wellness treatments—red-light therapy, dry needling, hyperbaric oxygen chambers—which she’s currently using as she recovers ...

As part of its long-term investment in women’s sports, Eli Lilly will be present at the WNBA All-Star Game through breast ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the company has agreed to acquire Verve Therapeutics. Eli Lilly and Company ...

As part of a growing trend of pharmaceutical giants reshoring their operations, AstraZeneca (AZN) announced Monday that it will invest $50 billion in U.S. manufacturing by 2030. This is the company’s ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts ...

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...